WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 531950
CAS#: 139262-76-3
Description: H2L5186303 is a potent and selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 values are 8.9, 1230 and 27354 nM).
MedKoo Cat#: 531950
Name: H2L5186303
CAS#: 139262-76-3
Chemical Formula: C26H20N2O8
Exact Mass: 488.122
Molecular Weight: 488.45
Elemental Analysis: C, 63.93; H, 4.13; N, 5.74; O, 26.20
Synonym: H2L5186303; H2L 5186303; H2L-5186303.
IUPAC/Chemical Name: (2Z,2'Z)-4,4'-(((1,3-phenylenebis(oxy))bis(4,1-phenylene))bis(azanediyl))bis(4-oxobut-2-enoic acid)
InChi Key: HZFPOTBCYPWQSH-DZDAAMPGSA-N
InChi Code: InChI=1S/C26H20N2O8/c29-23(12-14-25(31)32)27-17-4-8-19(9-5-17)35-21-2-1-3-22(16-21)36-20-10-6-18(7-11-20)28-24(30)13-15-26(33)34/h1-16H,(H,27,29)(H,28,30)(H,31,32)(H,33,34)/b14-12-,15-13-
SMILES Code: O(C1=CC(OC2=CC=C(NC(/C=C\C(O)=O)=O)C=C2)=CC=C1)C3=CC=C(NC(/C=C\C(O)=O)=O)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | H2L5186303 is a selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 = 9 nM in a LPA-elicited calcium mobilization assay). It inhibits LPA1 and LPA3 at much higher concentrations (IC50s = 27,354 and 4,504 nM, respectively). |
| In vitro activity: | The high cell invasion activity of human fibrosarcoma HT1080-M6 cells was significantly suppressed by H2L5186303, suggesting that LPA2 acts as a key regulator of malignant properties in HT1080 cells. Reference: Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. https://pubmed.ncbi.nlm.nih.gov/30093116/ |
| In vivo activity: | H2L5186303 showed strong suppressive efficacy in a single experimental protocol of ovalbumin (OVA)-induced allergic asthma when administered before OVA sensitization and challenge, such as suppression of airway hyper responsiveness, inflammatory cytokine levels, mucin production, and eosinophil numbers. Reference: Int J Mol Sci. 2022 Aug 28;23(17):9745. https://pubmed.ncbi.nlm.nih.gov/36077141/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 48.84 | 100.0 |
The following data is based on the product molecular weight 488.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Takahashi K, Minami K, Otagaki S, Ishimoto K, Fukushima K, Fukushima N, Honoki K, Tsujiuchi T. Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. doi: 10.1016/j.bbrc.2018.08.026. Epub 2018 Aug 7. PMID: 30093116. 2. Olianas MC, Dedoni S, Onali P. LPA1 is a key mediator of intracellular signalling and neuroprotection triggered by tetracyclic antidepressants in hippocampal neurons. J Neurochem. 2017 Oct;143(2):183-197. doi: 10.1111/jnc.14150. Epub 2017 Sep 11. PMID: 28815598. 3. Lee YJ, Im DS. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23(17):9745. doi: 10.3390/ijms23179745. PMID: 36077141; PMCID: PMC9456302. |
| In vitro protocol: | 1. Takahashi K, Minami K, Otagaki S, Ishimoto K, Fukushima K, Fukushima N, Honoki K, Tsujiuchi T. Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. doi: 10.1016/j.bbrc.2018.08.026. Epub 2018 Aug 7. PMID: 30093116. 2. Olianas MC, Dedoni S, Onali P. LPA1 is a key mediator of intracellular signalling and neuroprotection triggered by tetracyclic antidepressants in hippocampal neurons. J Neurochem. 2017 Oct;143(2):183-197. doi: 10.1111/jnc.14150. Epub 2017 Sep 11. PMID: 28815598. |
| In vivo protocol: | 1. Lee YJ, Im DS. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23(17):9745. doi: 10.3390/ijms23179745. PMID: 36077141; PMCID: PMC9456302. |
1: Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL. Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17(21):7457-64. doi: 10.1016/j.bmc.2009.09.022. PubMed PMID: 19800804; PubMed Central PMCID: PMC2771199.
